Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized tial with palliative end points

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2272-2279

  Bloomfield, D J ^a   Krahn, M D ^a   Neogi, T ^a   Panzarella, T ^a   Smith, T J ^a   Warde, P ^a   Willan, A R ^a   Ernst, S ^a   Moore, M J ^a   Neville, A ^a   Tannock, I F ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE; PREDNISONE;

ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG COST; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 7144261043     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2272     Document Type: Article

References (27)

1. American Cancer Society: Cancer Statistics 1997. Atlanta, GA, American Cancer Society, 1997
2. Tannock IF, Osoba D, Stockier MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
3. Denes AE: Chemotherapy with mitoxantrone in hormone-refractory prostate cancer. J Clin Oncol 15:410, 1997 (letter)
4. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
5. Aaronson N, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365-376, 1993
6. Krahn M, Gafni A: Discounting in the evaluation of health care interventions. Med Care 31:403-418, 1993
7. Holowaty EJ, Marrett LD, Fehringer G: Cancer Incidence in Ontario: Trends and Regional Variations. Toronto, Canada, Publications Ontario, The Ontario Cancer Treatment and Research Foundation, 1995
8. Hull R, Hirsh J, Sackett DL, et al: Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med 304:1561-1567, 1981
9. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. Oxford, United Kingdom, Oxford University Press, 1987, pp 39-61
10. Ontario Hospital Association: Ontario Guide to Case Costing. Toronto, Canada, Ontario Hospital Association, 1993
11. Warde P, Murphy T: Measuring the cost of palliative information. Can J Oncol 6:89-93, 1996 (suppl)
12. Williams C, Coyle D, Gray A, et al: European School of Oncology advisory report to the commission of the European communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care. Eur J Cancer 31A: 1410-1424, 1995
13. Torrance GW: Utility approach to measuring health-related quality of life. J Chron Dis 40:593-600, 1987
14. Read JL, Quinn RJ, Berwick DM, et al: Preferences for health outcomes comparison of assessment methods. Med Decis Making 4:315-329, 1984
15. O'Leary JF, Fairclough DL, Jankowski MK, et al: Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: Evidence for a plateau relationship. Med Decis Making 15:132-137, 1995
16. Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: An application of Fiellers theorem. Health Econom 5:297-305, 1996
17. Chaudary MA, Stearns SC: Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial. Stat Med 15:1447-1458, 1996
18. Gold MR, Siegel JE, Russell LB, et al: Cost-Effectiveness in Health and Medicine. New York, Oxford, Oxford University Press, 1996
19. Kantoff PW, Conaway M, Winer E, et al: Hydrocortisone with or without mitoxantrone in patients with hormone-refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B study comparing chemotherapy to best supportive care. J Clin Oncol 14:1748, 1996 (abstr)
20. Revicki DA, Kaplan RM: Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res 2:477-487, 1993
21. Torrance GW: Measurement of health state utilities for economic appraisal. J Health Econom 5:1-30, 1986
22. Naylor DC, Williams IJ, Basinski A, et al: Technology assessment and cost-effectiveness analysis: Misguided guidelines? Can Med Assoc J 148:921-924, 1993
23. Osoba D, Dancey J, Zee B, et al: Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst Monogr 20:107-111, 1996
24. Laupacis A, Feeny D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-481, 1992
25. Doyle C, Stockier M, Pintillie M, et al: Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 15:1000-1007, 1997
26. Jaakimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer. J Clin Oncol 8:1301-1309, 1990
27. McEwan AJB, Amyotte GA, McGowan DG, et al: A retrospective analysis of the cost-effectiveness of treatment with metastron in patients with prostate cancer metastatic to bone. Eur Urol 26:26-31, 1994